In our previous studies, overexpression of EPOR in RAMA 37-28 breast cancer cells altered the sensitivity of these cells to tamoxifen and paclitaxel via mechanism related to prolonged activation of AKT and ERK1/2 pathways, respectively [25,26]. The gene discussed is MAPK3; the disease is breast cancer.